

EQA round: BIL1/25 - Bilirubin Neonatal

Deadline: 21.3.2025

Setup: groups - M (measurement principle); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	CVPG = consensus of the participants' groups	UL = upper limit
N _{tot} = total number of the results	U _{AV} = expanded uncertainty of the assigned value (k = 2)	N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability						N _{eva}	N _{suc}	S _{rel} [%]
							AV	U _{AV}	D _{max}	LL	UL				
(215) Bilirubin total	[μmol/L]				127								127	123	97
Sample A		140	12	8,4	127		CVP	140	2,6	18%	114	166	127	126	99
(1) Jendrassik - Gróf		147	15	10	7	0							7		
(2) DCA, DPD		138	9,9	7,2	97	0							97		
(7) Oxidation-reduction methods		150	12	8,1	21	0							21		
Other					2	0							2		
							1x 0, 1x 5								
Sample B		272	24	8,7	127		CVP	272	5,2	18%	223	321	127	124	98
(1) Jendrassik - Gróf		284	15	5,3	7	0							7		
(2) DCA, DPD		266	19	7,2	97	0							97		
(7) Oxidation-reduction methods		298	18	6,2	21	0							21		
Other					2	0							2		
							1x 0, 1x 5								
(216) Bilirubin direct	[μmol/L]				117								113	104	92
Sample A		27,5	6,6	24	117								113	106	94
(2) DCA, DPD; (1) Abbott		22,5	1	4,6	19	0	CVPG	22,4	0,5	18%	18,3	26,5	19		
(2) DCA, DPD; (58) Beckman Coulter (AU)		38	2,3	6	23	0	CVPG	37,9	1,1	18%	31	44,8	23		
(2) DCA, DPD; (60) Roche		24	2,7	11	41	0	CVPG	23,9	0,98	18%	19,5	28,3	41		
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		29,2	3	10	16	0	CVPG	29,2	1,8	18%	23,9	34,5	16		
(7) Oxidation-reduction methods; (179) Siemens		26,8	1,9	6,9	6	0	CVPG	26,8	2,6	18%	21,9	31,7	6		
Other					12	0							8		
							1x 0/0, 2x 1/1, 1x 1/58, 2x 1/60, 1x 1/149, 2x 2/162, 1x 7/70, 1x 7/77, 1x 99/60								
Sample B		45,7	9,5	21	117								113	107	95
(2) DCA, DPD; (1) Abbott		40	2,1	5,4	19	0	CVPG	40	1,1	18%	32,8	47,2	19		
(2) DCA, DPD; (58) Beckman Coulter (AU)		59,4	3,2	5,4	23	0	CVPG	59,5	1,6	18%	48,7	70,3	23		
(2) DCA, DPD; (60) Roche		40,2	5,8	14	41	0	CVPG	40,1	2,2	18%	32,8	47,4	41		
(7) Oxidation-reduction methods; (162) Siemens (Atellica)		47,6	3,1	6,5	16	0	CVPG	47,7	1,8	18%	39,1	56,3	16		
(7) Oxidation-reduction methods; (179) Siemens		45,4	2,4	5,4	6	0	CVPG	45,4	3,4	18%	37,2	53,6	6		
Other					12	0							8		
							1x 0/0, 2x 1/1, 1x 1/58, 2x 1/60, 1x 1/149, 2x 2/162, 1x 7/70, 1x 7/77, 1x 99/60								